FDA Clearance Tracker · P250009
SQUID Liquid Embolic Agent (LEA)
Last checked: Nov 19, 2026Latest source record: Jan 30, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Jan 30, 2026
Approved
Time to decision
315 days
Received Mar 21, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P250009
- Device name
- SQUID Liquid Embolic Agent (LEA)
- Applicant
- Balt USA, LLC
- Applicant location
- Irvine, CA
- Received
- Mar 21, 2025
- Decided
- Jan 30, 2026
- Decision
- Approved
- Supplements
- 2 in FDA's data for this PMA. See them on the FDA record
Device type
- Device type
- Neurovascular Liquid Embolic Agent (SGU)
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
The SQUID Liquid Embolic Agent is indicated for the embolization of the middle meningeal artery (MMA) as an adjunct to usual care treatment in patients with symptomatic chronic subdural hematoma(s) (SDH) measuring 10 mm or greater in thickness in whom an intervention is deemed necessary as determined by a neurosurgeon.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code SGU. The earliest in FDA's data is P030004-S035, decided Dec 8, 2025.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Balt USA, LLC
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- SLIM Microcatheter510(k)
K260199 · Decided Jul 13, 2026 · 172 days after receipt
Device type: Catheter, Percutaneous, Neurovasculature (QJP) · Cardiology
K254223 · Decided Apr 16, 2026 · 108 days after receipt
Device type: Catheter, Percutaneous, Neurovasculature (QJP) · Cardiology
K254221 · Decided Jan 27, 2026 · 29 days after receipt
Device type: Device, Neurovascular Embolization (HCG) · Neurology & Neurosurgery
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.